Abbott Laboratories Pakistan Ltd
Abbott Laboratories Pakistan Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services in Pakistan.
Business. Abbott Laboratories Pakistan Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services in Pakistan.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Abbott Laboratories Pakistan Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services in Pakistan.
Abbott Laboratories Pakistan Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.02, indicating minimal leverage relative to its equity base of 31.63 billion PKR. The company holds total assets of 46.82 billion PKR against total liabilities of 15.19 billion PKR, resulting in a current ratio of 2.32, which suggests adequate short-term liquidity to meet obligations. Despite the low debt levels, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, implying that cash and equivalents are insufficient to cover total debt obligations outright, though the low absolute debt level of 488 million PKR mitigates immediate solvency concerns.
Profitability metrics demonstrate strong operational efficiency, with a return on equity (ROE) of 16.81% and a return on assets (ROA) of 11.35%. The company generated a gross profit of 26.80 billion PKR on revenues of 75.40 billion PKR, yielding a gross margin of approximately 35.5%. Operating income stood at 13.58 billion PKR, leading to a net income of 7.97 billion PKR, which reflects a net margin of roughly 10.6%. These returns indicate effective capital deployment and cost management within the local market context, although specific cohort median comparisons are unavailable to benchmark these performance levels against industry peers.
- The company exhibits strong profitability with an ROE of 16.81% and ROA of 11.35%, driven by a 10.6% net margin.
- Capital structure is highly conservative with a debt-to-equity ratio of 0.02, though net cash is negative after debt subtraction.
- Liquidity is assessed as medium risk, with a current ratio of 2.32 providing adequate short-term coverage.
- Dilution risk is low, as basic and diluted shares outstanding are identical at 97.90 million.
- Analyst estimates suggest a mean EPS of 71.90 PKR, providing a forward-looking earnings benchmark.
- Lack of historical data prevents trend analysis, limiting the assessment of growth trajectory and consistency.
Bull / Bear case
Generated · model-assistedNet income surged 98.6% year-over-year to PKR 7.97 billion, demonstrating strong recent profitability momentum.
Free cash flow improved dramatically by 600% year-over-year, reaching PKR 5.59 billion in the latest period.
The company maintains a conservative debt-to-equity ratio of 0.02, well below the cohort median of 0.40.
The four-year revenue CAGR of -13.3% indicates a persistent long-term contraction in sales volume.
Net income CAGR of -7.0% over four years suggests underlying earnings instability despite recent spikes.
Medium liquidity risk flags potential challenges in meeting short-term obligations or operational cash needs.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Cash Conversion Ratiooperating_cash_flow / net_income
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Return On Assetsnet_income / total_assets
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Abbott Laboratories Pakistan Ltd Market data — financials · 2026-07-07
- Abbott Laboratories Pakistan Ltd Market data — analyst estimates · 2026-07-07